Marketing opportunity 


Therakind is looking for additional partners to market Jylamvo® in US, China, Japan, parts of the EU, and ROW.

Jylamvo is an EMA authorised oral liquid methotrexate, a cytotoxic oncological / immunosuppressant product.

The product was granted a European Marketing Authorisation by the European Medicines Agency (EMA) on 29 March 2017.

Jylamvo is authorised in the EU for use in the following indications:

In rheumatological and dermatological diseases

  • Active rheumatoid arthritis in adult patients.

  • Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non‑steroidal anti‑inflammatory drugs (NSAIDs) has been inadequate.

  • Severe, treatment‑refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.

In oncology

  • Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over 

To register interest in Jylamvo® or to discuss partnering/ licencing opportunities please contact